L-Sox5, Sox6 and Sox9 control essential steps of the chondrocyte differentiation pathway  by Lefebvre, V. et al.
Osteoarthritis and Cartilage (2001) 9 Supplement A, S69–S75
© 2001 OsteoArthritis Research Society International 1063–4584/01/0A0S69+07 $35.00/0
doi:10.1053/joca.2001.0447, available online at http://www.idealibrary.com onL-Sox5, Sox6 and Sox9 control essential steps of the chondrocyte
differentiation pathway
V. Lefebvre*, R. R. Behringer and B. de Crombrugghe*
Department of Molecular Genetics, The University of Texas, MD Anderson Cancer Center, Houston, Texas,
U.S.A.
Summary
Objective: This work was carried out to identify transcription factors controlling the differentiation of mesenchymal cells into chondrocytes.
Design: We delineated a cartilage-specific enhancer in the collagen type 2 gene (Col2a1) and identified transcription factors responsible for
the activity of this enhancer in chondrocytes. We then analyzed the ability of these transcription factors to activate specific genes of the
chondrocyte differentiation program and control cartilage formation in vivo.
Results: A 48-bp sequence in the first intron of Col2a1 drove gene expression specifically in cartilage in transgenic mouse embryos. The
transcription factors L-Sox5, Sox6, and Sox9 bound and cooperatively activated this enhancer in vitro. They belong to the Sry-related family
of HMG box DNA-binding proteins, which includes many members implicated in cell fate determination in various lineages. L-Sox5, Sox6,
and Sox9 were coexpressed in all precartilaginous condensations in mouse embryos and continued to be expressed in chondrocytes until
the cells underwent final hypertrophy. Whereas L-Sox5 and Sox6 are highly homologous proteins, they are totally different from Sox9 outside
the HMG box domain. The three proteins cooperatively activated the Col2a1- and aggrecan genes in cultured cells. Heterozygous mutations
in SOX9 in humans lead to campomelic dysplasia, a severe and generalized skeletal malformation syndrome. Embryonic cells with a
homozygous Sox9 mutation were unable to form cartilage in vivo and activate essential chondrocyte marker genes. Preliminary data
indicated that the mutation of Sox5 and Sox6 in the mouse led to severe skeletal malformations.
Conclusions: L-Sox5, Sox6, and Sox9 play essential roles in chondrocyte differentiation and, thereby, in cartilage formation. Their discovery
will help to understand further the molecular mechanisms controlling chondrogenesis in vivo, uncover genetic mechanisms underlying
cartilage diseases, and develop novel strategies for cartilage repair. © 2001 OsteoArthritis Research Society International
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During the organogenesis of the vertebrate embryo, cells
from three separate mesenchymal lineages independently
undergo chondrocytic differentiation and form the multiple
cartilages of the primary skeleton. Cranial neural crest cells
give rise to the cartilages of the nose, face, middle ear and
neck; sclerotome cells form the vertebral column and ribs;
and lateral plate mesoderm cells form the laryngeal carti-
lages, sternum, and cartilages of the limbs and girdles.
Despite different cellular origins and despite positional and
anatomical differences, all individual cartilage elements
form following essentially the same chondrogenesis differ-
entiation program1–3. The same program is also adopted in
adult organisms in skeleton regeneration mechanisms fol-
lowing bone fracture4. Precursor cells first condense and
resume their mesenchymal phenotype, including expres-
sion of the genes for the collagens 1 and 3. They activate aS69unique set of genes characteristic of the chondrocyte
genetic early program and start to accumulate abundant
amounts of highly specialized extracellular matrix. In this
matrix, the collagens 2, 9, and 11 assemble into a fibrillar
network that provides the tissue structural strength.
Entrapped in this network, a highly hydrophilic gel of
proteoglycans, mostly contributed by aggrecan, provides
the characteristic resilience of cartilages. Subsequently,
embryonic cartilages have two different fates. Nasal,
tracheal, articular and other cartilages persist throughout
life, with structural and functional properties similar to those
of embryonic cartilages. The mature chondrocytes of these
permanent cartilages express a resting phenotype qualita-
tively very close to that of embryonic chondroblasts. In
contrast, the most part of the primary cartilaginous tem-
plates of the limb and trunk skeleton and of some cranio-
facial skeletal structures is progressively replaced by bone
through the process called endochondral ossification, start-
ing in embryogenesis and ending when growth ceases. The
chondrocytes of these cartilages proceed to further steps of
differentiation. They first undergo multiple rounds of pro-
liferation, associated with abundant extracellular matrix
production, and then mature into hypertrophic chondro-
cytes, which express a new genetic program including
expression of the gene for collagen 10. They finally apop-
tose when cartilages are invaded by capillary blood vessels
and bone-forming cells.
S70 V. Lefebvre et al.: The chondrocyte differentiation pathwayChondrogenesis is thus a multi-step cell differentiation
pathway, genetically characterized by a complex cascade
of specific gene activations and inactivations. Many
types of molecules have been shown to play roles in the
control of chondrogenesis1–3,5,6. They are classed into two
main categories. Patterning factors trigger the formation
and determine the fate, shape and size of individual
skeletal elements. They include a number of bone morpho-
genetic proteins and fibroblast growth factors, their signal-
ing molecules, and transcription factors such as homeobox
factors. They are each typically found in only a restricted
number of skeletal elements. Differentiation factors, in
contrast, are defined as molecules involved in the specific
control of one or several steps of the chondrocyte differen-
tiation pathway and they are expressed in every cartilage.
They also include diffusible growth factors, receptors and
intracellular signaling mediators, as well as transcription
factors. Noticeably, the secreted factor parathyroid-
hormone-related peptide (PTHrp), its receptor (PTH/PTHrp
receptor), and the extracellular indian hedgehog (Ihh) sig-
naling molecule control the differentiation of prehyper-
trophic chondrocytes into hypertrophic cells7,8. Because
the majority of chondrogenesis regulatory factors have
been identified recently, the precise mode of action of most
of them is still largely unknown. It is also clear that many
players remain to be identified. Our main goal over the last
years has been to identify and characterize transcription
factors that act as master control factors to determine the
switch to chondrogenesis and control specifically and
directly the activation of chondrocyte marker genes.
Our initial hypothesis of the existence of master
chondrogenic differentiation factors was based on the
examples of other cell lineages that are derived from the
same mesenchymal precursor cells as chondrocytes, and
that have been shown to be each governed by a specific
set of master transcription factors. For instance, in the
myogenic cell lineage, four basic helix-loop-helix muscle
regulatory factors (MyoD, myogenin, Myf-5, and MRF4),
the myocyte enhancer factor 2 (MEF2) group of MADS-box
regulators, Pax-3 and the muscle LIM protein (MLP) co-
operate to positively control transcription of muscle-specific
differentiation genes9. In the osteoblastic lineage, the factor
Cbfa1/Osf2, a runt family member, is expressed in all
osteoblastic precursor and differentiated cells, is absolutely
required to form bones in vivo, and directly activates a
number of marker osteoblastic genes3. In the adipoblast
pathway, C/EBP beta and delta, ADD-1/SREBP-1, and
the peroxisome proliferator activated receptor-gamma
(PPAR gamma) play pivotal roles in the differentiation of
adipocytes and expression of cell-specific genes10.
In this review, we will summarize the experimental evi-
dences that led us and other groups to identify the first
chondrogenic transcription factor, Sox9. We will also
present the pieces of evidence that we have accumulated
that strongly suggest that L-Sox5 and Sox6 are additional
chondrogenic transcription factors, presumably working in
cooperativity with Sox9 in the early stages of the chondro-
cyte differentiation pathway.Identification of candidate chondrogenic
transcription factors
In order to qualify as master chondrogenic transcription
factor, a candidate molecule must meet a number of
criteria. First, it has to be expressed during chondrogenesis
specifically and be present in all sites of chondrogenesis. Itis, nevertheless, conceivable that its expression pattern be
not entirely restricted to the chondrocyte differentiation
pathway as its chondrogenic action could be specified by
cooperativity with other chondrogenic factors. Second, the
factor has to be directly involved in the activation of
chondrocyte-specific genes. Therefore, it must bind directly
or indirectly to regulatory regions in chondrocyte marker
genes. Third, the mutation of the gene for this factor must
have dramatic consequences on the formation of cartilages
in vivo, proving the requirement for this factor in one or
several steps of the chondrocyte differentiation program.
Following these criteria, we undertook a search for
chondrogenic transcription factors. We designed our initial
strategy on their postulated ability to bind to regulatory
sequences in chondrocyte marker genes. Our first goal was
thus to identify cis-acting regulatory elements that are
responsible for the chondrocyte-specific expression of
these genes. In order to identify factors acting in the early
steps of chondrogenesis, we chose the gene for collagen 2
(Col2a1). Indeed, expression of this gene is highly cell-
specific, starts as soon as precartilaginous mesenchymal
condensations form, and remains abundant in fully differ-
entiated chondrocytes11. Using in parallel the transgenic
mouse approach and transient transfection experiments in
cultured cells, we first confirmed earlier reports that had
suggested that the first intron of Col2a1 was needed for
cartilage-specific expression12,13. We then showed that
Col2a1 promoter and upstream sequences were not
needed for chondrocyte-specific expression14, and upon
progressive delineation of the first intron chondrocyte regu-
latory sequences14,15, identified a 48-bp segment as the
minimum DNA element needed to direct expression of
a reporter gene specifically to chondrocytes in mouse
embryos and in cultured cells16. In agreement with our
data17, Krebsbach and collaborators (1996) delineated a
100-bp Col2a1 chondrocyte-specific enhancer that encom-
passed the 48-bp sequence, and Bell and collaborators
(1997) delineated a 309-bp cartilage-specific COL2A1
enhancer that included the 3′ half of the 48-bp enhancer.
Four tandem copies of the 48-bp enhancer were needed to
obtain high levels of reporter gene expression, presumably
because this short sequence lacked cis-acting elements
that may be needed in the endogenous gene to amplify the
signal induced by the chondrocyte-specific transcription
factors binding to the minimal enhancer.
We then used the 48-bp enhancer sequence to identify
the nuclear proteins that were responsible for the specific
activation of the enhancer in chondrocytes. Several protein
binding sites in this enhancer were shown to be required for
enhancer activity in chondrocytes and also to form a large
protein-DNA complex with chondrocyte-specific nuclear
proteins in gel retardation assays (Fig. 1A and B)18,19.
These sites all resemble a consensus binding site for
proteins with a high-mobility-group (HMG) DNA-binding
domain. Upon both literature and experimental screening,
we found the chondrocyte-specific protein-enhancer com-
plex to be made of Sox9, Sox6, and a new long form of
Sox5, which we called L-Sox5 (Fig. 1C)19,20. These three
proteins are members of the Sox subclass of HMG DNA-
binding proteins. Bell and collaborators (1997) showed that
an additional HMG-like protein-binding site located 50-bp
downstream of the 48-bp enhancer in the COL2A1 gene
also bound Sox9 and contributed to the activity of the
309-bp enhancer in chondrocytes. These data led us
to postulate that L-Sox5, Sox6, and Sox9 may form a trio
of chondrogenic factors and further experiments were
designed to test this hypothesis.
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Sox proteins are a subfamily of over 20 members
within the large family of proteins that harbor one or
several so-called high-mobility-group (HMG) DNA-binding
domains21,22. The HMG domain is a 79-amino-acid motif
consisting of three α-helices arranged in a twisted L-shape.
The HMG domain of Sox proteins are 50% identical or
more to that of SRY, a testis-determining factor. The identity
includes the conservation of specific amino acid residues
important for DNA contact and conformational structure.
Based on identity within and outside the HMG domain, Sox
proteins are classed into seven subgroups, designated A to
G. Members of different subgroups show differences in
DNA-binding affinity and vary greatly in structural organiz-
ation, transactivation capability, and ability to interact and
act in synergism with other proteins.
The Sox HMG domain specifically recognizes DNA
sequences with the degenerate consensus C(A/T)TTG(A/
T)(A/T)23,24. In contrast to most other types of transcription
factors, which contact DNA in the major groove, Sox (and
other HMG proteins) target the minor groove of DNA.
Binding induces a sharp DNA bend, estimated at about
70–90°, such that the concave binding surface of the HMG
domain perfectly fits to the DNA groove25. Based on this
bending property, Sox proteins are believed to act as
architectural proteins that, like the HMGI/Y and LEF-1 HMG
proteins26, organize local chromatin structure to promote
assembly of macromolecular regulatory complexes involv-
ing transcription factors bound to DNA at proximal sites. In
addition to this presumed accessory function, several Sox
proteins, including Sox9, feature a potent transcription
activation domain and are able to act as typical transcrip-
tional activators20,27. Several Sox proteins have also beenshown to synergize with cell-specific transcription factors,
including POU-domain proteins, and it has been suggested
that this partner mechanism may account for the specific
functions of Sox proteins in different cell types28. For
instance, Sox2 synergizes with Oct3/4 to activate a cell-
specific fibroblast growth factor 4 gene enhancer in embry-
onic stem cells29, but synergizes with a different factor,
called EF3, to activate a cell-specific -crystallin gene
enhancer in lens cells30.
Over the last years, Sox proteins have been increasingly
demonstrated to be required for cell fate specification in
various cell lineages and mutations of their genes in the
mouse and in humans have been shown to lead to severe
developmental defects and diseases. For instance, Sry,
whose gene maps to the Y chromosome, is involved in
testis and male differentiation; mutations in SRY lead to sex
reversal in XY humans31,32, and expression of Sry in XX
mice leads to male differentiation33. Other examples
include the requirement of Sox1 for lens development,
Sox4 for endocardial ridge development and B cell differ-
entiation, and Sox10 for determination of neural crest and
glial cells (review in Ref. 22). These data thus add weight to
our hypothesis that L-Sox5, Sox6, and Sox9 could be
involved in the specification of the chondrocyte lineage.Fig. 1. A Col2a1 48-bp chondrocyte-specific enhancer binds
L-Sox5, Sox6, and Sox9. (A) Sequence of the 48-bp enhancer with
underlining of four HMG-like binding sites. (B) In gel retardation
assay, the 48-bp enhancer forms a large complex (arrow) with
nuclear proteins from primary chondrocytes (lane 1) and from the
highly differentiated rat chondrosarcoma cell line (lane 2) but not
with nuclear proteins from nonchondrocytic cells such as 10T1/2
fibroblasts (lane 3), rat osteosarcoma cells (lane 4) and C2C12
myoblasts (lane 5). (C) The chondrocyte-specific protein-enhancer
complex (arrow) is made of L-Sox5, Sox6, and Sox9. Specific
antibodies against L-Sox5, Sox6, and Sox9 supershift (arrow
head) the protein-enhancer complex only partially when tested
individually, but essentially completely when tested in combination.Fig. 2. Comparison of the structural organization of Sox5, L-Sox5,
Sox6, and Sox9. Each protein is represented as a block, with
numbers referring to the first and last amino acids. HMG, DNA-
binding domain; coiled-coil, dimerization domain; PQA, proline-,
alanine-, and glutamine-rich domain; TA, transactivation domain.
Hatched boxes represent regions whose coding exons are subject
to alternative splicing. Dotted lines link regions of homology
between proteins.STRUCTURAL ORGANIZATION OF L-SOX5, SOX6 AND SOX9
L-Sox5 and Sox6 belong to the subgroup D of Sox
proteins. The two proteins are overall 67% identical to each
other, and share more than 90% identity in the HMG
domain and in a coiled-coil domain (Fig. 2)19. This latter
domain, of 82 residues, is made of a leucine-zipper associ-
ated with a glutamine-rich protein segment. It is located
in the N-terminus of L-Sox5 and Sox6, and is not present
in Sox5, a spermatid-specific shorter product of the
same Sox5 gene. By mediating the formation of protein
homodimers and heterodimers (L-Sox5/Sox6), this domain
allows L-Sox5 and Sox6 to bind with a much higher affinity
to DNA containing two adjacent HMG-binding sites than to
DNA harboring a single site. By comparison, Sox9, which
does not homodimerize, binds with similar affinity to both
types of DNA. This finding implicates that L-Sox5 and
Sox6, in contrast to monomeric Sox proteins, must recog-
nize their target genes at pairs of adjacent HMG sites.
Sox9 belongs to the Sox subgroup E. Its HMG domain
displays only 50% identity with that of L-Sox5 and Sox6,
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different from L-Sox5 and Sox6. As already mentioned
above, Sox9 has no dimerization domain but features a
potent transactivation domain at its C-terminus. It also
harbors a distinctive domain, called ‘PQA’ and made of 41
residues of solely proline, glutamine and alanine, whose
function is still unknown.
Hence, the structural organization of L-Sox5, Sox6, and
Sox9 and their functional properties in vitro suggested that
L-Sox5 and Sox6 could fulfill similar roles in vivo. Their
roles may be complementary to those of Sox9 but must be
clearly distinct from those of Sox9.L-SOX5, SOX6 AND SOX9 ARE COEXPRESSED DURING
CHONDROGENESIS
In situ hybridization experiments have revealed coex-
pression of the transcripts for L-Sox5, Sox6 and Sox9 in
every site of chondrogenesis in the mouse embryo19,34,35.
The three types of transcripts are detectable as early as
precursor mesenchymal cells start to form precartilaginous
condensations and remain abundantly expressed in every
fully formed cartilage onward, in parallel with Col2a1 tran-
scripts. During endochondral ossification, expression of the
three Sox genes and of Col2a1 is high in resting and
proliferating chondrocytes, and rapidly turned off when
chondrocytes undergo hypertrophy in the end of their
differentiation pathway (Fig. 3). These data are thus con-
sistent with a role for each of the three Sox genes in
specifying chondrogenesis at early steps and maintaining
the chondrocyte phenotype in fully differentiated cells.
As L-Sox5 and Sox6, which are very similar proteins, are
coexpressed in chondrogenesis, we postulated that they
may have redundant roles in this cell differentiation
pathway.
In addition to their expression in chondrogenesis, Col2a1
and the three Sox genes are also expressed in some areas
of the brain and neural tube of mouse developing embryos.
Each of the three Sox genes is also found at a generally
low level in a restricted number of other tissues in embry-
onic and adult mice, although never altogether as in
chondrogenic tissues. Each of the three Sox proteins is
thus believed to have also specific functions in some
non-cartilaginous tissues. For instance, Sox9 is expressed
in the Sertoli cells of testis where it contributes to cell fate
specification and male differentiation36,37. Short transcripts
of Sox6 and Sox5 (encoding the short Sox5 protein) arefound in mature testis, where they may play a role in the
latest stages of the differentiation pathway of spermatid
cells38,39.L-SOX5, SOX6 AND SOX9 COOPERATE TO ACTIVATE
CHONDROCYTE MARKER GENES
Binding of L-Sox5, Sox6, and Sox9 to the Col2a1
enhancer was shown to mediate high levels of activation of
this enhancer in nonchondrogenic cells19. Indeed, when
Col2a1 reporter constructs, which harbored the 48-bp
enhancer or a larger enhancer segment, were transfected
in fibroblasts together with expression plasmids for the
three Sox proteins, activation of the constructs was found
to be much higher when the three Sox proteins were
coexpressed than when either one was expressed alone
(Fig. 4A). Moreover, the three Sox proteins were able not
only to act cooperatively in the activation of these Col2a1
reporter constructs, but they were also able to cooperate to
stimulate at high levels the expression of the endogenous
Col2a1 gene in 10T1/2 fibroblasts and in the poorly differ-
entiated MC615 chondrocytic cell line (Fig. 4B). These
experiments thus strongly suggest that the three Sox
proteins act in concert as direct activators of the collagen 2
gene in chondrocytes.
Moreover, it appears likely that the three Sox proteins
may also target other chondrocyte marker genes that are
coexpressed with Col2a1 in the early stages of the
chondrocyte differentiation program. Indeed, upon over-
expression in MC615 cells, the three Sox proteins also
cooperated to upregulate expression of the aggrecan
gene19. Two chondrocyte-specific enhancer-elements in
the promoter of the collagen 11 Col11a2 gene contain a
cluster of HMG-like binding sites, similar to that present in
the 48-bp Col2a1 enhancer40. These Col11a2 HMG-like
sites were also shown to bind L-Sox5, Sox6, and Sox9
and were needed for the expression of these enhancers in
the cartilages of mouse embryos. Altogether, these data
suggest that the three Sox proteins may be involved in the
activation of the most essential cartilage matrix genes and
thus control a critical part of the chondrogenesis program.Fig. 3. The transcripts for L-Sox5, Sox6, and Sox9 are coexpressed with those for collagen 2 in growth plate cartilages. In situ hybridization
of longitudinal sections through the tibia of a 17.5-dpc mouse embryo. Chondrocytes in hyaline cartilage and proliferative zones of growth
plates actively expressed the transcripts for collagen 2, L-Sox5, Sox6, and Sox9. Hypertrophic chondrocytes no longer expressed the Sox
genes, and Col2a1 expression was progressively replaced by Col10a1 (collagen 10) expression. Osteoblasts and cells in surrounding
tissues were expressing the Col1a1 gene (collagen 1).L-SOX5, SOX6, AND SOX9 ARE ESSENTIAL FOR CARTILAGE
FORMATION IN VIVO
In 1994, Foster and collaborators, and Wagner and
collaborators reported that heterozygous mutations in
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chondrodysplasia that is called campomelic dysplasia, and
that is often associated with XY sex reversal. Campomelic
dysplasia is characterized by bowing of long bones, and
malformations in many cartilages and cartilage-derived
skeletal structures. Death most often occurs at or soon
after birth due to respiratory distress. It is an autosomal
dominant disorder, believed to be due to SOX9 haplo-
insufficiency in most cases. It has, however, been sug-
gested that in some cases the SOX9 mutations could lead
to expression of a SOX9 mutant protein that could interfere
in a dominant-negative manner with wild-type SOX9,
increasing the severity of the disease20.
To further study the function of Sox9 in vivo, Bi
and collaborators41 generated both heterozygous andhomozygous Sox9 mutant mouse embryonic stem (ES)
cells. Because humans with a SOX9 heterozygous mu-
tation die at or soon after birth, the behavior of these
mutant ES cells was analyzed in mouse embryo chimeras.
In mouse chimeras derived from wild-type blastocysts
injected with Sox9 heterozygous mutant cells, cartilages
were found to contain both mutant and wild-type cells and
both types of cells were able to express chondrocyte-
specific markers such as Col2a1 and aggrecan. In contrast,
in mouse chimeras generated using Sox9 homozygous
mutant ES cells, cartilages were always made of wild-type
cells only. Sox9 homozygous null cells were excluded from
cartilages in a cell-autonomous fashion at the condensing
stage of prechondrocytic mesenchymal cells, and as carti-
lages formed, Sox9 null cells accumulated at the periphery
of cartilages, forming patches of ectopic mesenchymal
tissue. These cells expressed the Sox9 null alleles but were
unable to express chondrocyte-specific markers such as
Col2a1, Col9a2, Col11a2 and aggrecan. In teratomas
generated by injecting wild-type or Sox9 heterozygous null
embryonic stem cells subcutaneously into syngeneic mice,
many different tissue types developed, including cartilages.
In contrast, when Sox9 homozygous null cells were used,
teratomas formed that contained multiple tissue types but
no cartilage could be detected. Altogether, these results
thus identified Sox9 as the first transcription factor that is
essential for chondrocyte early differentiation and cartilage
formation.
To determine the roles that L-Sox5 and Sox6 play in
chondrogenesis in vivo, we have recently inactivated their
genes in the mouse using standard procedures of homolo-
gous DNA recombination into embryonic stem cells (our
unpublished data). Preliminary analysis of mutant mice
indicates severe abnormalities in essentially all endochon-
dral skeletal elements and proves genetic interaction
between Sox5 and Sox6. Overall, the skeletal defects are
similar to those seen in mice with mutations in the Col2a1,
aggrecan, or link protein genes42–45. The preliminary
results thus support the notion that L-Sox5 and Sox6
control critical genetic events in the chondrocyte differen-
tiation pathway. Further analysis of Sox5/Sox6 double
mutant mice is in progress to define the precise roles of
L-Sox5 and Sox6 in vivo and determine whether they are
also absolutely required for chondrocyte differentiation and
cartilage formation, as is Sox9.Fig. 4. L-Sox5, Sox6, and Sox9 cooperatively activate a Col2a1
reporter construct and the endogenous Col2a1 gene. (A) 10T1/2
fibroblasts were transfected with expression plasmids encoding no
protein (−), L-Sox5 (L5), Sox6 (S6), or SOX9 (S9), and Col2a1
reporter constructs. The p309 construct contained a 309-bp
Col2a1 promoter; this construct, which has no activity in chondro-
cytes, was not significantly activated by the Sox proteins. The
p309-(2x231) construct, which harbored two copies of a 231-bp
Col2a1 segment including the 48-bp enhancer, was activated at
high levels by the three Sox proteins in cooperativity. (B) Northern
blots of RNA from MC615 cells transiently transfected with
expression plasmids for no protein (−) or either one of the three
Sox proteins. Coexpression of the three Sox proteins strongly
upregulated expression of Col2a1 in MC615 cells. Col2a1 RNA
levels in RCS rat chondrosarcoma cells are shown for comparison.
Hybridization with an 18S rRNA probe was done as a control for
RNA loading.CONCLUSIONS AND PERSPECTIVES
Human, mouse, and molecular genetic approaches have
recently converged to successfully identify the first master
chondrogenic factor, Sox9, and two additional master
candidates, L-Sox5 and Sox6. Sox9’s role in cartilage
formation was first recognized upon detection of mutations
in and around the SOX9 gene in humans with campomelic
dysplasia. Sox9, L-Sox5 and Sox6 were then found to be
expressed concomitantly with the cartilage marker Col2a1
in all precartilaginous condensations and fully formed
cartilages of mouse embryos, and to cooperatively activate
Col2a1 through direct binding to a cartilage-specific
intron-1 enhancer. Gene inactivation experiments in the
mouse then demonstrated the master role of Sox9 in the
conversion of mesenchymal precursor cells into differenti-
ated chondrocytes. Indeed, without Sox9, cells committed
to the chondrocytic lineage were unable to form precarti-
laginous condensations and to activate a number of carti-
lage markers, including Col2a1 and aggrecan. Preliminary
S74 V. Lefebvre et al.: The chondrocyte differentiation pathwaydata in mouse mutants have indicated that L-Sox5 and
Sox6 are also essential for proper chondrogenesis in vivo.
The identification of these first three chondrogenic differ-
entiation factors constitutes an important step in unraveling
genetic mechanisms controlling chondrogenesis but it also
prompts a number a new questions. Concerning, for
instance, the precise mode of action of each of L-Sox5,
Sox6, and Sox9. Do they really form a trio of chondrogenic
transcription factors, or are they just three players in a
larger orchestra of cell-specific factors? How do they co-
operate with each other at the molecular level? Are they
involved at the same step of chondrocyte differentiation or
at successive steps? What is their panel of target genes?
Questions can also be raised concerning the mechanisms
whereby their genes are turned on in prechondrocytic cells
and off in hypertrophic chondrocytes. What are the roles of
bone morphogenetic proteins, fibroblast growth factors,
sonic and indian hedgehog, and many other regulatory and
signaling factors in controlling or modulating the expression
of the three Sox genes or the activity of the three Sox
proteins? As L-Sox5, Sox6, and Sox9 are essential during
chondrogenesis in the embryo, questions can also be
raised concerning their implication in the maintenance of
the chondrocyte phenotype in permanent cartilages, and in
cartilage degeneration and regeneration processes in the
adult.
The answer to all these questions will provide new
important insights into our understanding of how L-Sox5,
Sox6 and Sox9 control essential steps in the chondro-
genesis pathway. In parallel, it is to hope that additional
factors will soon be identified that have important roles in
chondrogenesis, in parallel with the three Sox proteins or
upstream and downstream of them. Piece by piece, we will
then be able to progressively reconstitute the whole net-
work of genetic cascades that specify the complex and
multistep differentiation of chondrocytes.Acknowledgments
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